Back to Search Start Over

Sarbanes - Oxley Act proving costly for US biotech

Source :
SCRIP World Pharmaceutical News. March 4, 2005 Issue 3034, p16, 1 p.
Publication Year :
2005

Abstract

The enforcement of the Sarbanes-Oxley Act has increased the workload and cost compliance for companies in the United States, as it demands increased transparency and accountability in companies. An analysis is done on the economic influence of the Act on the biotechnology industry of the country.

Details

Language :
English
ISSN :
01437690
Issue :
3034
Database :
Gale General OneFile
Journal :
SCRIP World Pharmaceutical News
Publication Type :
Periodical
Accession number :
edsgcl.130951942